Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
38.65 HKD | +1.71% | +16.82% | +9.05% |
May. 02 | Hong Kong Shares Rise After HKMA, US Fed Hold Off Rate Hikes | MT |
May. 01 | HSBC must prioritise Asian expertise in surprise CEO search | RE |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its low valuation, with P/E ratio at 6.55 and 5.86 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.05% | 95.12B | B | ||
+7.71% | 98.09B | B- | ||
-10.51% | 82.72B | B+ | ||
+20.02% | 74.13B | D+ | ||
+8.49% | 30.52B | B | ||
+20.29% | 28.07B | B | ||
+6.64% | 27.62B | A | ||
+1.98% | 17.24B | C+ | ||
-10.88% | 15.04B | B | ||
+20.62% | 12.68B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 601318 Stock
- 2318 Stock
- Ratings Ping An Insurance Group Company